Kangsheng Biosciences' IPO on the Shenzhen Stock Exchange has been terminated. They specialize in researching, producing, and selling blood purification products.

On July 11th, Guangzhou Kangsheng Biotechnology Co., Ltd. (referred to as Kangsheng Biotechnology) had its IPO review status changed to terminated by the Shenzhen Stock Exchange. This decision was made because Kangsheng Biotechnology and the sponsor withdrew their application for listing, in accordance with the "Shenzhen Stock Exchange Stock Issuance and Listing Review Rules (2024 Revision)", Article 62. According to the prospectus, Kangsheng Biotechnology was established in 2001 and is an innovative medical device company mainly engaged in the research, production, and sales of blood purification products. After more than twenty years of development, the company's products and services cover the areas of blood dialysis and blood adsorption, with the main products being blood dialysis concentrates, blood dialysis powders, blood dialysis filters, protein A immunoadsorption columns, and disposable bilirubin plasma adsorbers, as well as providing blood dialysis treatment services. In the field of blood dialysis, the blood dialysis concentrates and blood dialysis powders developed and produced by the company belong to the third category of medical devices and are clinically used to prepare dialysis solutions for blood dialysis treatment. The company has been deeply involved in the blood purification industry for many years, and with its core technological advantages and industry experience, it has stable product quality and occupies a leading market share in the industry. In the field of blood adsorption, the company uses genetically engineered recombinant protein A as the adsorption ligand, and agarose gel as the carrier, to develop and produce the "Kanber" brand protein A immunoadsorption column. The protein A immunoadsorption column belongs to the third category of medical devices and can rapidly and effectively remove pathogenic antibodies from the blood, and can be used in the treatment of various autoimmune diseases and organ transplant rejection reactions. Currently, this type of product has been clinically used in many well-known tertiary hospitals in China, achieving good clinical treatment results. The net proceeds from this offering, after deducting issuance expenses, will be fully invested in the following projects in order of priority. Financially, Kangsheng Biotechnology achieved revenues of approximately RMB 374 million, RMB 402 million, RMB 422 million, and RMB 209 million in the years 2019, 2020, 2021, and January to June 2022 respectively, with net profits of approximately RMB 56.8664 million, RMB 66.9991 million, RMB 81.0371 million, and RMB 40.2652 million respectively.